Erna Peters

440 total citations
7 papers, 361 citations indexed

About

Erna Peters is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Erna Peters has authored 7 papers receiving a total of 361 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 2 papers in Oncology and 2 papers in Hematology. Recurrent topics in Erna Peters's work include Angiogenesis and VEGF in Cancer (4 papers), Protease and Inhibitor Mechanisms (2 papers) and Nitric Oxide and Endothelin Effects (1 paper). Erna Peters is often cited by papers focused on Angiogenesis and VEGF in Cancer (4 papers), Protease and Inhibitor Mechanisms (2 papers) and Nitric Oxide and Endothelin Effects (1 paper). Erna Peters collaborates with scholars based in Netherlands, United States and Slovakia. Erna Peters's co-authors include Pieter Koolwijk, Victor W.M. van Hinsbergh, Cornelis J.F. Van Noorden, Annemie Collen, Susanne M. Smorenburg, Florea Lupu, Cornelis F.M. Sier, Roeland Hanemaaijer, Francesco Blasi and Nicolai Sidénius and has published in prestigious journals such as Blood, Arteriosclerosis Thrombosis and Vascular Biology and Thrombosis and Haemostasis.

In The Last Decade

Erna Peters

7 papers receiving 356 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Erna Peters Netherlands 7 200 113 81 75 46 7 361
Jaakko Kaukonen Finland 5 370 1.9× 128 1.1× 208 2.6× 90 1.2× 19 0.4× 8 559
Masahiko Zuka Japan 7 160 0.8× 49 0.4× 151 1.9× 101 1.3× 45 1.0× 15 440
Jeremy G. T. Wurtzel United States 12 300 1.5× 140 1.2× 164 2.0× 117 1.6× 36 0.8× 21 485
Sorina Grisaru‐Granovsky Israel 5 189 0.9× 174 1.5× 86 1.1× 301 4.0× 60 1.3× 9 540
Humayun Mirza United States 4 162 0.8× 195 1.7× 68 0.8× 278 3.7× 22 0.5× 8 531
Christel Herzog Germany 5 342 1.7× 106 0.9× 97 1.2× 20 0.3× 12 0.3× 6 453
Miriam Maoz Israel 9 227 1.1× 235 2.1× 94 1.2× 394 5.3× 66 1.4× 12 676
Véronique Dubernard France 12 147 0.7× 82 0.7× 39 0.5× 219 2.9× 12 0.3× 20 430
ES Barnathan United States 11 168 0.8× 254 2.2× 74 0.9× 166 2.2× 8 0.2× 15 483
Léa Plantureux France 5 185 0.9× 81 0.7× 169 2.1× 50 0.7× 43 0.9× 8 379

Countries citing papers authored by Erna Peters

Since Specialization
Citations

This map shows the geographic impact of Erna Peters's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erna Peters with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erna Peters more than expected).

Fields of papers citing papers by Erna Peters

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erna Peters. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erna Peters. The network helps show where Erna Peters may publish in the future.

Co-authorship network of co-authors of Erna Peters

This figure shows the co-authorship network connecting the top 25 collaborators of Erna Peters. A scholar is included among the top collaborators of Erna Peters based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erna Peters. Erna Peters is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Zerp, Shuraila F., Stefan R. Vink, Pieter Koolwijk, et al.. (2008). Alkylphospholipids inhibit capillary-like endothelial tube formation in vitro: antiangiogenic properties of a new class of antitumor agents. Anti-Cancer Drugs. 19(1). 65–75. 17 indexed citations
2.
Rookmaaker, Maarten B., Marianne C. Verhaar, Cindy J.M. Loomans, et al.. (2005). CD34 + Cells Home, Proliferate, and Participate in Capillary Formation, and in Combination With CD34 Cells Enhance Tube Formation in a 3-Dimensional Matrix. Arteriosclerosis Thrombosis and Vascular Biology. 25(9). 1843–1850. 33 indexed citations
3.
Hensbergen, Yvette van, Erna Peters, Sareena Rana, et al.. (2003). Aminopeptidase inhibitor bestatin stimulates microvascular endothelial cell invasion in a fibrin matrix. Thrombosis and Haemostasis. 90(11). 921–929. 8 indexed citations
4.
Koolwijk, Pieter, Erna Peters, Herbert A. Weich, et al.. (2001). Involvement of VEGFR-2 (kdr/flk-1) but not VEGFR-1 (flt-1) in VEGF-A and VEGF-C-induced tube formation by human microvascular endothelial cells in fibrin matrices in vitro. Angiogenesis. 4(1). 53–60. 51 indexed citations
5.
Koolwijk, Pieter, Nicolai Sidénius, Erna Peters, et al.. (2001). Proteolysis of the urokinase-type plasminogen activator receptor by metalloproteinase-12: implication for angiogenesis in fibrin matrices. Blood. 97(10). 3123–3131. 88 indexed citations
6.
Manolopoulos, Vangelis G., Sandra Liekens, Pieter Koolwijk, et al.. (2000). Inhibition of angiogenesis by blockers of volume-regulated anion channels. General Pharmacology The Vascular System. 34(2). 107–116. 42 indexed citations
7.
Collen, Annemie, Susanne M. Smorenburg, Erna Peters, et al.. (2000). Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro.. PubMed. 60(21). 6196–200. 122 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026